AN2 Therapeutics (ANTX) Net Equity Issued and Repurchased (2021 - 2025)

AN2 Therapeutics (ANTX) has reported Net Equity Issued and Repurchased for 5 consecutive years, with $48000.0 the latest figure, recorded in Q3 2025.

• In Q3 2025, Net Equity Issued and Repurchased rose 108.7% year-over-year to $48000.0; the TTM figure through Dec 2025 stood at $86000.0 (down 41.5% YoY), while the FY2025 annual figure was $86000.0, down 41.5% from the prior year.
• Net Equity Issued and Repurchased rose to $48000.0 in Q3 2025 per ANTX's latest filing, from $38000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $79.7 million in Q1 2021 and bottomed at -$4.5 million in Q4 2022.
• Historically, Net Equity Issued and Repurchased has averaged $11.8 million across 5 years, with a median of $86000.0 in 2024.
• Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased surged 516.31% — and 2025, when it sank 69.35%.
• AN2 Therapeutics' Net Equity Issued and Repurchased stood at $79.7 million in 2021, then plunged by 105.64% to -$4.5 million in 2022, then soared by 516.31% to $18.7 million in 2023, then tumbled by 99.88% to $23000.0 in 2024, then soared by 108.7% to $48000.0 in 2025.
• Business Quant data shows ANTX's Net Equity Issued and Repurchased at $48000.0 in Q3 2025, $38000.0 in Q1 2025, and $23000.0 in Q3 2024.